AMWL vs. AUGX, MPLN, INCR, CRDL, ELMD, RENB, IMAB, SKYE, SYRS, and CTMX
Should you be buying American Well stock or one of its competitors? The main competitors of American Well include Augmedix (AUGX), MultiPlan (MPLN), InterCure (INCR), Cardiol Therapeutics (CRDL), Electromed (ELMD), Renovaro (RENB), I-Mab (IMAB), Skye Bioscience (SKYE), Syros Pharmaceuticals (SYRS), and CytomX Therapeutics (CTMX). These companies are all part of the "medical" sector.
Augmedix (NASDAQ:AUGX) and American Well (NYSE:AMWL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk.
87.1% of Augmedix shares are held by institutional investors. Comparatively, 56.1% of American Well shares are held by institutional investors. 11.0% of Augmedix shares are held by insiders. Comparatively, 12.9% of American Well shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
American Well received 28 more outperform votes than Augmedix when rated by MarketBeat users. However, 50.00% of users gave Augmedix an outperform vote while only 47.76% of users gave American Well an outperform vote.
Augmedix has a net margin of -41.95% compared to Augmedix's net margin of -137.32%. Augmedix's return on equity of -46.76% beat American Well's return on equity.
Augmedix has higher earnings, but lower revenue than American Well. Augmedix is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.
In the previous week, Augmedix had 24 more articles in the media than American Well. MarketBeat recorded 25 mentions for Augmedix and 1 mentions for American Well. Augmedix's average media sentiment score of 0.42 beat American Well's score of -0.04 indicating that American Well is being referred to more favorably in the news media.
Augmedix has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, American Well has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
Augmedix presently has a consensus price target of $3.88, suggesting a potential upside of 220.25%. American Well has a consensus price target of $1.00, suggesting a potential upside of 104.54%. Given American Well's stronger consensus rating and higher possible upside, equities research analysts plainly believe Augmedix is more favorable than American Well.
Summary
Augmedix beats American Well on 10 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding AMWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
American Well Competitors List
Related Companies and Tools
